Filter Results:
(619)
Show Results For
- All HBS Web
(619)
- People (4)
- News (103)
- Research (424)
- Events (3)
- Multimedia (4)
- Faculty Publications (261)
Show Results For
- All HBS Web
(619)
- People (4)
- News (103)
- Research (424)
- Events (3)
- Multimedia (4)
- Faculty Publications (261)
- April 2023 (Revised January 2024)
- Background Note
Note on Healthcare in Ghana
By: Regina E. Herzlinger and Ben Creo
This note provides an overview of the healthcare system in Ghana. It discusses the public and private sector as well as traditional medical practice. It also discusses the country’s pharmaceutical industry. It is recommended as a companion to Professor Regina... View Details
Keywords: Africa; Pharmaceutical Companies; Pharmacy Benefit Manager; Health Care; Health Care Costs; Health Care Delivery; Health Care Entrepreneurship; Telehealth; Health Equity; Governing Rules, Regulations, and Reforms; Health Care and Treatment; Business and Government Relations; Pharmaceutical Industry; Pharmaceutical Industry; Ghana
Herzlinger, Regina E., and Ben Creo. "Note on Healthcare in Ghana." Harvard Business School Background Note 323-112, April 2023. (Revised January 2024.)
- 01 Feb 2022
- Book
Innovation Isn’t Just for Startups: How Big Companies Can Succeed
What if more managers at big corporations channeled some of the same magic that helped Tesla CEO Elon Musk and Amazon founder Jeff Bezos lead their startups to great success? Large companies are actually fertile ground for innovation;... View Details
Keywords: by Lane Lambert
- Teaching Interest
Why is There No Cure for Health Care?
Teaching Fellow for Professor David Cutler - Harvard College Course EMREAS 20
View Details- June 2004
- Case
Aventis SA (B): A Company is Born
By: Joshua D. Margolis and Carin-Isabel Knoop
Supplements the (A) case. View Details
Keywords: Problems and Challenges; Mergers and Acquisitions; Horizontal Integration; Organizational Design; Organizational Culture; Pharmaceutical Industry; United States
Margolis, Joshua D., and Carin-Isabel Knoop. "Aventis SA (B): A Company is Born." Harvard Business School Case 404-108, June 2004.
- February 2019 (Revised July 2019)
- Case
Sales Force Management at Nobel Ilac
By: Doug J. Chung and Gamze Yucaoglu
Nobel Ilac was a Turkish generic pharmaceutical company marketing more than 100 drugs in 20 countries and, as of 2017, had over 2,500 employees worldwide. Nobel had implemented a transformation strategy—more specifically, a customer segmentation plan—whereby the sales... View Details
Keywords: Sales Strategy; Compensation; Employee Retention; Recruiting; Pharmaceuticals; Salesforce Management; Strategy; Organizational Design; Human Resources; Compensation and Benefits; Employees; Retention; Recruitment; Pharmaceutical Industry; Turkey
Chung, Doug J., and Gamze Yucaoglu. "Sales Force Management at Nobel Ilac." Harvard Business School Case 519-067, February 2019. (Revised July 2019.)
- May 2015
- Case
Transforming Alkermes into a Global Biopharmaceutical Company
By: C. Fritz Foley and Nicholas Haas
In the summer of 2011, Jim Frates, CFO of Alkermes faced choices about how to finance the acquisition of Dublin, Ireland-based Elan Drug Technologies (EDT)—a deal that was expected to close in the fall. The case describes the history of Alkermes, provides information... View Details
Keywords: Financing; Debt; Merger; CFO; Financial Management; Pharmaceutical Industry; Pharmaceutical Industry; United States; Europe
Foley, C. Fritz, and Nicholas Haas. "Transforming Alkermes into a Global Biopharmaceutical Company." Harvard Business School Case 215-079, May 2015.
- April 2017
- Case
Imprimis (A)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case examines the strategic choices and evolving business model of Imprimis Pharmaceuticals from the perspective of CEO Mark Baum. The (A) case provides a brief history of the company and of the compounding business, outlining the challenges faced by Imprimis in... View Details
Keywords: Strategy; Healthcare; Drug Compounding; Pharmaceuticals; Compounding; Drug Development; Decision-making; Mark Baum; Imprimis; Small Business; Decisions; Cost vs Benefits; Business Strategy; Business Model; Decision Choices and Conditions; Pharmaceutical Industry; United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (A)." Harvard Business School Case 717-426, April 2017.
- 01 Mar 2007
- News
Pharma Suits a Farm Gal
GRAHAM: From rodeo to CEO. Amylin Pharmaceuticals CEO Ginger Graham (MBA ’86) had a good year in 2006, with Amylin stock up as much as 45 percent, with Byetta and Symlin, its two innovative diabetes drugs, performing well, and with the... View Details
- October 2014 (Revised April 2023)
- Case
Gilead: Hepatitis C Access Strategy (A)
By: V. Kasturi Rangan, Vikram Rangan and David E. Bloom
Gilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the... View Details
Keywords: Healthcare; Pharmaceuticals; Pricing; Access To Care; Emerging Markets; Health Care and Treatment; Price; Strategy; Ethics; Pharmaceutical Industry; Pharmaceutical Industry
Rangan, V. Kasturi, Vikram Rangan, and David E. Bloom. "Gilead: Hepatitis C Access Strategy (A)." Harvard Business School Case 515-025, October 2014. (Revised April 2023.)
- November 2016
- Case
QuintilesIMS: Biosimilar Marketing in England
By: John A. Quelch and Emily C. Boudreau
QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical... View Details
Keywords: Health; Pharmaceutical Industry; Biotech; Marketing; Health Care and Treatment; Biotechnology Industry; England
Quelch, John A., and Emily C. Boudreau. "QuintilesIMS: Biosimilar Marketing in England." Harvard Business School Case 517-054, November 2016.
- January 2017 (Revised October 2018)
- Case
Novartis: A Transformative Deal
By: David Collis and Ashley Hartman
When Joe Jimenez became CEO of Swiss-based Novartis in 2010, replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and... View Details
Keywords: Novartis; GlaxoSmithKline; Asset Swap; Acquisitions; Divestiture; Strategy Alignment; Pharmaceuticals; Strategy; Business Strategy; Corporate Strategy; Diversification; Consolidation; Mergers and Acquisitions; Pharmaceutical Industry
Collis, David, and Ashley Hartman. "Novartis: A Transformative Deal." Harvard Business School Case 717-453, January 2017. (Revised October 2018.)
- 26 Apr 2023
- Cold Call Podcast
How Martine Rothblatt Started a Company to Save Her Daughter
- October 2022 (Revised September 2024)
- Case
mPharma: Scaling Access to Affordable Primary Care in Africa
By: Regina E. Herzlinger and Ben Creo
mPharma hopes to scale up to create the largest pan-African healthcare company ever to provide much-needed primary care in retail pharmacies; a reliable, fairly priced supply of drugs; and micro-insurance for drugs. They must prioritize launching a telemedicine... View Details
Keywords: Africa; Pharmaceutical Companies; Pharmacy Benefit Manager; Health Care; Health Care And Treatment; Health Care Costs; Health Care Delivery; Health Care Entrepreneurship; Telehealth; Health Equity; Corporate Strategy; Social Entrepreneurship; Equity; Growth and Development Strategy; Expansion; Product Launch; Customer Value and Value Chain; Social Enterprise; Multinational Firms and Management; Pharmaceutical Industry; Pharmaceutical Industry; Africa
Herzlinger, Regina E., and Ben Creo. "mPharma: Scaling Access to Affordable Primary Care in Africa." Harvard Business School Case 323-033, October 2022. (Revised September 2024.)
- October 2014 (Revised May 2017)
- Teaching Note
Pfizer and AstraZeneca: Marketing an Acquisition (A) & (B)
By: John A. Quelch
- 04 Feb 2019
- Blog Post
Presenting…an Alternative to Company Presentations: Evercore Grabs Attention with Interactive Events
case study. When they added two more ingredients to the recipe – a focus on a familiar industry, amplified by media exposure the audience would recognize – they arrived at the heart of their presentation; a “live” case study about Evercore’s role in a recent M&A:... View Details
- February 2015 (Revised November 2015)
- Case
Building an Integrated Biopharma Company: Crucell (A)
By: Richard G. Hamermesh, Marianne Van Der Steen and Susan S. Harmeling
By 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space,... View Details
Keywords: Biotechnology; Biopharmacy Company; Licensing; Licensing Agreements In Biopharmacy; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Partners and Partnerships; Entrepreneurship; Growth and Development Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Netherlands
Hamermesh, Richard G., Marianne Van Der Steen, and Susan S. Harmeling. "Building an Integrated Biopharma Company: Crucell (A)." Harvard Business School Case 815-085, February 2015. (Revised November 2015.)
- 01 Dec 2013
- News
Your Own Medicine
help build new muscle—had been one of several potential treatments the Secklers chased to no avail, often stuck following promising science to dead ends. That changed three years ago, when former pharmaceutical executive Gene Williams... View Details
- 28 Feb 2020
- News
Filling the White Space
companies involved in research into psychedelic compounds for medical use. (Compass has been granted a US patent that covers a method of obtaining psilocybin to treat drug-resistant depression; the treatment is in a phase IIb clinical... View Details
- March 2014
- Case
Novartis' Sandoz: Between Generics and Pharma
By: Krishna Palepu and Carin-Isabel Knoop
Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What... View Details
Keywords: Global Strategy And Leadership; Managing Within A Multi-Business Organization; Generic Pharmaceuticals; Global Strategy
Palepu, Krishna, and Carin-Isabel Knoop. "Novartis' Sandoz: Between Generics and Pharma." Harvard Business School Case 114-033, March 2014.
- November 2013 (Revised September 2015)
- Supplement
GlaxoSmithKline in China (B)
By: John A. Quelch and Margaret L. Rodriguez
In 2013, Chinese investigators detained four GSK employees for allegedly bribing health care staff to sell GSK pharmaceuticals. A month later, GSK's Asia Pacific regional president, Abbas Hussain, said the company would help identify corrupt practices. Two days later,... View Details
Keywords: Public Health; Pharmaceuticals; China; Bribery; CSR; Hong Bao; Health Care; Drug; GlaxoSmithKline; GSK; Witty; Government; Marketing; Health; Health Care and Treatment; Corporate Social Responsibility and Impact; Corporate Strategy; Corporate Governance; Business and Government Relations; Ethics; Pharmaceutical Industry; China; United Kingdom; United States
Quelch, John A., and Margaret L. Rodriguez. "GlaxoSmithKline in China (B)." Harvard Business School Supplement 514-050, November 2013. (Revised September 2015.)